Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 23, 2021 at 02:33 pm IST
Share
Shanghai Haohai Biological Technology Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 382.585 million compared to CNY 153.614 million a year ago. Operating income was CNY 114.812 million compared to operating loss of CNY 29.705 million a year ago. Net income was CNY 96.992 million compared to net loss of CNY 24.855 million a year ago. Basic earnings per share from continuing operations was CNY 0.55 compared to basic loss per share from continuing operations of CNY 0.14 a year ago.
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.